Latest revenue
$0
as of 2026-03-31
Latest net income
$-500.0K
as of 2026-03-31
Net margin
—
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $17.4M
- Enterprise value
- $17.4M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $0.54
- 52-wk low
- $0.09
- Beta
- —
- Shares out
- 96.5M
5-year trend
What this company does
Overview We are a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. Our primary focus is the sales and marketing of our LuViva® Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for…
AI summary unavailable — showing raw filing excerpt
Generated from GTHP's filing dated 2026-03-31
Key risks
A purchase of our securities involves a high degree of risk. Our business or operating or financial condition could be harmed due to any of the following risks. Accordingly, investors should carefully consider these risks in making a decision as to whether to purchase, sell or hold our securities. In addition, investors should note that the risks described below are not the only risks facing us. Additional risks not presently known to us, or risks that do not seem significant today, may impair our business operations in the future. You should carefully consider the risks described below, as well as the other information contained in this Annual Report on Form 10-K and the documents…
AI summary unavailable — showing raw filing excerpt
Generated from GTHP's filing dated 2026-03-31
Profitability
Gross margin
74.4%
160.6%Operating margin
-309.3%
99.0%Net margin
-416.7%
98.8%Return on equity
53.2%
7.6%Return on assets
-241.4%
37.6%Leverage
Debt / equity
-1.22×
4.8%Long-term debt / equity
-0.00×
60.2%Debt / assets
553.6%
21.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $0 | — | $-500.0K | -17.1% | — |
Q4 2025 2025-12-31 | $590.0K | +58900.0% | $-1.2M | -86.5% | -206.1% |
Q3 2025 2025-09-30 | $60.0K | — | $-742.0K | -13.5% | -1236.7% |
Q2 2025 2025-06-30 | $117.0K | — | $-811.0K | -14.4% | -693.2% |
Q1 2025 2025-03-31 | $0 | -100.0% | $-427.0K | -6.2% | — |
Q4 2024 2024-12-31 | $1.0K | — | $-652.0K | — | -65200.0% |
Q3 2024 2024-09-30 | $0 | — | $-654.0K | +3.4% | — |
Q2 2024 2024-06-30 | $0 | -100.0% | $-709.0K | +54.5% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Electromedical & Electrotherapeutic Apparatus · SIC 3845
Your notes
Keep private notes on GTHP — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$35.0K
Insider selling
$0
Net activity
+$35.0K
Distinct insiders
3
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns GTHP
No institutional holdings on file for GTHP yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once GTHP's latest filing finishes processing.